## Edgar Filing: DUSA PHARMACEUTICALS INC - Form 3/A

## DUSA PHARMACEUTICALS INC

Form 3/A June 15, 2001

FORM 3		OMB APPROVAL			
		OMB Number: Estimated average hours per response	burden		
	ATES SECURITIES WASHINGTON, D.C.	AND EXCHANGE COMMI	ISSION		
INITIAL STATE	MENT OF BENEFICI	AL OWNERSHIP OF SE	ECURITIES		
Section 17(a) of	the Public Utili	the Securities Ex ty Holding Company tment Company Act	_		
1. Name and Address of	Reporting Person	*			
Cooper Hill Partners	, LLC				
(Last) (Fir	st)	(Middle)			
230 Park Avenue,					
	eet)				
New York, N	Y	10169			
(City) (St	ate)	(Zip)			
2. Date of Event Requir	ing Statement (M	onth/Day/Year)			
March 13, 2001					
3. IRS or Social Securi	ty Number of Rep	orting Person (Vol	luntary)		
4. Issuer Name and Tick	er or Trading Sy	 mbol			
DUSA Pharmaceuticals	Inc. DUS	A 			
5. Relationship of Repo	rting Person to	Issuer (Check all	applicable)		
<pre>[ ] Director [x] 10% Owner [ ] Officer (give ti [ ] Other (Specify begins)</pre>					
6. If Amendment, Date of	f Original (Mont	 h/Day/Year)			

# Edgar Filing: DUSA PHARMACEUTICALS INC - Form 3/A

March 29, 2001			
7. Individual or Joint/	Group Filing (Che	ck applicable li	ne)
<pre>[] Form filed by One [x] Form filed by Mo</pre>			
TABLE INON-DERIVATIVE	SECURITIES BENEF	ICIALLY OWNED	
1. Title of Security 2. (Instr. 4)	Securities Beneficially	Form: Direct (D) or Indirect	4. Nature of Indirect Beneficial Ownership (Instr. 5)
common stock	1,682,900	I	
Nature of Indirect Bene	ficial Ownership	(Intr. 4)	
LLC has the power to vopartnerships and, according securities. Jeffrey Cases and the securities of the	dingly, may be dedin is the managi	emed the "beneficing member of Cooperation	cial owner" of such per Hill Partners, LLC
securities beneficially (Print or Type Response	owned directly o		
			(Over) SEC 1473 (7-96)
FORM 3 (continued)			
TABLE II - DERIVATIVE S. (E.G., PUTS, CALLS, WAR			ITIES)
1. Title of Derivative (Instr. 4)	Expi	ration Date th/Day/Year) e Expiration	of Securities Underlying Derivative
			Title Amount or

Number of Shares

## Edgar Filing: DUSA PHARMACEUTICALS INC - Form 3/A

4.	Conversion or Exercise Price of Derivative Security	Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	Nature of Indirect Beneficial Ownership (Instr. 5)	

#### Explanation of Responses:

Note 1 The Reporting Person may be considered a "group" as explained in Table I, Item 4.: however each member of the group disclaims beneficial ownership of any securities owned by such other persons.

If space is insufficient, SEE Instruction 6 for procedure.

DATED: June 15, 2001

/s/ Jeffrey Casdin

Jeffrey Casdin
For Cooper Hill Partners, LLC,
the General Partner of CLSP,
L.P.; CLSP II, L.P.; CLSP/SBS
I, L.P. and CLSP/SBS II, L.P.;
and Individually

<sup>\*\*</sup>Intentional misstatements or omissions of facts constitute Federal Criminal Violations. SEE 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).